Cutera Announces Expansion of FDA Indications for enlighten Laser Platform

- December 17th, 2018

CUTERA (Nasdaq:CUTR) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, today announces the U.S. Food and Drug Administration (FDA) approves clearance of an additional indication, for acne scars, on its premier enlighten® laser platform. As quoted in the press release: Dr. Neil Sadick, a world-renowned dermatologist, of Sadick Dermatology, … Continued

CUTERA (Nasdaq:CUTR) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, today announces the U.S. Food and Drug Administration (FDA) approves clearance of an additional indication, for acne scars, on its premier enlighten® laser platform.

As quoted in the press release:

Dr. Neil Sadick, a world-renowned dermatologist, of Sadick Dermatology, NY, NY stated, “PICO Genesis FX elevates enlighten’s existing skin revitalization capabilities and introduces a fractional approach to treating acne scars, textural concerns and aging skin on all skin types. Its novel Micro Lens Array (MLA) treats the upper layers of the epidermis and dermis which generate collagen stimulation and remodeling of the skin. The expansion of this new fractional treatment means my patients will receive more efficacious results with little-to-no downtime for active lifestyles.”

“The FDA clearance for acne scars represents another achievement for the enlighten platform and showcases Cutera’s on-going focus on innovation and clinical advancements in laser and light-based technology,” said James Reinstein, President and CEO of Cutera. “The system’s multiple wavelengths, dual pulse durations, and high power are all industry-leading features that offer practitioners a broad range of treatment settings and cleared indications. We will continue to develop technologies that advance the medical aesthetics industry and meet the needs of our customers and their patients.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Tags

Leave a Reply